Harmony Biosciences Holdings Cash Flow Conversion Efficiency
Harmony Biosciences Holdings cash flow conversion efficiency. Based on the latest financial reports, Harmony Biosciences Holdings (HRMY) has a cash flow conversion efficiency ratio of 0.093x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($92.43 Million) by net assets ($999.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Harmony Biosciences Holdings (2018–2025)
Cash flow conversion efficiency of Harmony Biosciences Holdings from 2018 to 2025. This chart illustrates how Harmony Biosciences Holdings's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Harmony Biosciences Holdings for real-time trading data and today's change.
Harmony Biosciences Holdings Cash Flow Conversion Ratio Explained
Harmony Biosciences Holdings cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Harmony Biosciences Holdings Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harmony Biosciences Holdings ranked by their cash flow conversion efficiency. Also see Harmony Biosciences Holdings market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sinochem International Corp
SHG:600500
|
0.046x |
|
Lotus Health Group Co
SHG:600186
|
0.043x |
|
Y.H. Dimri Construction & Development Ltd
TA:DIMRI
|
-0.148x |
|
Firstsource Solutions Limited
NSE:FSL
|
0.102x |
|
CPI Europe AG
VI:CPI
|
0.027x |
|
Pandox AB (publ)
ST:PNDX-B
|
0.016x |
|
Aether Industries Limited
NSE:AETHER
|
0.047x |
|
Empresas Cablevisión S.A.B. de C.V
MX:CABLECPO
|
0.177x |
Annual Cash Flow Conversion Efficiency for Harmony Biosciences Holdings (2018–2025)
The table below shows the annual cash flow conversion efficiency of Harmony Biosciences Holdings from 2018 to 2025. Review HRMY free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $870.22 Million | $348.20 Million | 0.400x | +19.98% |
| 2024-12-31 | $659.15 Million | $219.82 Million | 0.333x | -29.01% |
| 2023-12-31 | $466.99 Million | $219.39 Million | 0.470x | +31.00% |
| 2022-12-31 | $402.84 Million | $144.47 Million | 0.359x | -32.14% |
| 2021-12-31 | $186.51 Million | $98.56 Million | 0.528x | +1820.38% |
| 2020-12-31 | $97.18 Million | $-2.98 Million | -0.031x | -100.47% |
| 2019-12-31 | $-11.59 Million | $-75.44 Million | 6.512x | +1468.26% |
| 2018-12-31 | $81.53 Million | $-38.80 Million | -0.476x | -- |
About Harmony Biosciences Holdings
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that … Read more